Aurora Capital LLC is a boutique investment bank and securities firm founded in 1994. Investment banking is comprised of an experienced team of professionals specializing in the life science sector, which utilizes a rigorous process in the selection of investment ideas and investment banking clients.
As of March 22, 2013, affiliates of Aurora Capital were elected and represented a majority of members of the Board of Directors of what was then Cortex Pharmaceuticals, Inc. (CORX). The Board of Directors was subsequently expanded and now is comprised of six members. On December 16, 2015, Cortex Pharmaceuticals, Inc. was re-named and is now RespireRx Pharmaceuticals Inc. (OTCQB: RSPI). On August 16, 2016, the shareholders voted in favor of a 1 for 325 reverse stock split, which was effected on September 1, 2016. For more information, view recent filings and news on the SEC website or by visiting RespireRx's website at www.RespireRx.com.
In addition to in-house expertise and experienced personnel, Aurora retains the services of a network of qualified scientific, medical, and other advisors. Aurora's enduring objective is attempting to achieve equitable valuations for our investment banking clients while concurrently providing investor returns commensurate with the risks inherent in emerging technologies. On the securities and brokerage side of the business, we are teams of knowledgeable and experienced registered representatives with depth of understanding and broad capabilities to meet the challenges of our customers' investing needs and who also have unique access to the securities offerings of the investment banking department, the resources of our clearing firm and the broad understanding of the life science sector.
Aurora is based in Bridgehampton, NY, with offices in: Rockland County and Glen Cove, Long Island, New York. We are dedicated to serving life science companies and their investors as well as our customers’ general investing needs. We seek to: (i) provide valuable or undiscovered investment opportunities to our investing clients and (ii) provide high quality service to a corporate finance client base which may be overlooked or underserved by the major and regional investment banking organizations primarily due to company or transaction size.